Your browser doesn't support javascript.
loading
A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration.
Sime, Fekade B; Stuart, Janine; Butler, Jenie; Starr, Therese; Wallis, Steven C; Pandey, Saurabh; Lipman, Jeffrey; Roberts, Jason A.
Afiliación
  • Sime FB; School of Pharmacy, Centre for Translational Anti-infective Pharmacodynamics, The University of Queensland, Brisbane, Australia.
  • Stuart J; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Butler J; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Starr T; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Wallis SC; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Pandey S; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Lipman J; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Roberts JA; School of Pharmacy, Centre for Translational Anti-infective Pharmacodynamics, The University of Queensland, Brisbane, Australia; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia; University of Queensland Centre for Clinical Research, Faculty of Medicine
Int J Antimicrob Agents ; 52(4): 506-509, 2018 Oct.
Article en En | MEDLINE | ID: mdl-30031203
ABSTRACT
This article reports a pharmacokinetic case study of intravenous posaconazole in a 49-year-old male patient with intra-abdominal sepsis and hypoalbuminaemia receiving continuous venovenous haemodiafiltration. Concentration-time data following 300 mg intravenous posaconazole was analysed using a population pharmacokinetics approach. The 300-mg intravenous dose appears to be adequate for the treatment of yeast infections; however, for the treatment of invasive aspergillosis in isolated cases of critically ill patients with hypoalbuminaemia, the current dosing may not achieve desired exposure, although steady state exposure data are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Triazoles / Hemodiafiltración / Sepsis / Hipoalbuminemia / Infecciones Intraabdominales / Antifúngicos Tipo de estudio: Prognostic_studies Límite: Humans / Male / Middle aged Idioma: En Revista: Int J Antimicrob Agents Año: 2018 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Triazoles / Hemodiafiltración / Sepsis / Hipoalbuminemia / Infecciones Intraabdominales / Antifúngicos Tipo de estudio: Prognostic_studies Límite: Humans / Male / Middle aged Idioma: En Revista: Int J Antimicrob Agents Año: 2018 Tipo del documento: Article País de afiliación: Australia
...